Standout Papers

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database 2022 2026 2023 202493
  1. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database (2022)
    Léa Hoisnard, Bénédicte Lebrun‐Vignes et al. Scientific Reports

Immediate Impact

16 standout
Sub-graph 1 of 5

Citing Papers

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
NF-κB in biology and targeted therapy: new insights and translational implications
2024 Standout
2 intermediate papers

Works of Léa Hoisnard being referenced

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
2022 Standout
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
2022

Author Peers

Author Last Decade Papers Cites
Léa Hoisnard 65 69 45 109 16 272
Khader N. Mustafa 42 67 16 128 19 294
Kenichiro Matoba 41 45 27 130 13 328
Linda Carli 29 93 21 203 19 296
Evange Romas 30 58 12 114 12 286
Shikai Geng 26 94 15 89 13 314
Luigi Virgolini 43 29 10 68 21 289
D. Felix-Davies 15 100 65 139 13 302
Teresa Contreras 33 55 33 16 19 246
Amy Wasserman 55 73 4 169 14 311
Danielle Levine 69 141 7 61 11 287

All Works

Loading papers...

Rankless by CCL
2026